Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Locus Biosciences has disclosed receiving a $23.9 million investment from BARDA, intended to back the inaugural Phase 2 study of its groundbreaking CRISPR-crafted phage treatment.

Onward Therapeutics has begun recruiting for an initial phase clinical study of their innovative dual-targeted antibody, OT-A201, which engages with two distinct immune control points.

PharmAbcine Initiates Dosing in Early-Stage Study for PMC-309 with KEYTRUDA (pembrolizumab) in Subjects Facing Severe Solid Cancers.

Harbour BioMed has been granted FDA approval to initiate human trials for their bispecific antibody, HBM9027, in the U.S.

Biosion has received approval from the FDA for its investigational new drug application concerning BSI-082, an innovative monoclonal antibody targeting SIRPα.

CDR-Life revealed the FDA's approval for clinical trial application for their drug, CDR404, aimed at addressing solid tumor conditions.

Long-term results show Opdivo combined with Yervoy outlasts Sunitinib in survival outcomes for advanced or metastatic kidney cancer patients who haven't received prior treatment over an 8-year period.

Vanda Pharmaceuticals Granted Green Light by FDA to Advance with Experimental Antisense Oligonucleotide Therapy, VCA-894A, for Managing Charcot-Marie-Tooth Disease, Subtype 2S.

Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.